SEARCH

SEARCH BY CITATION

References

  • 1
    Lawrence, RC, Helmick, CG, Arnett, FC, Et, Al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 77899.
  • 2
    Gabriel, SE, Fehring, RA. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986–1990. J Clin Epidemiol 1992; 45: 10414.
  • 3
    Frost & Sullivan Market Intelligence. Pain management markets (August 1993). Report no. 894–52. Mountain View (CA): Frost & Sullivan, 1995.
  • 4
    Rothschild, BM. Cost savings and prescribing protocols for nonsteroidal anti-inflammatory drugs. JAMA 1996; 276: 5256.
  • 5
    Anonymous. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 190515.
  • 6
    Eccles, M, Freemantle, N, Mason, J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-steroidal Anti-inflammatory Drug Guideline Development Group. BMJ 1998; 317: 52630.
  • 7
    Silverstein, FE, Faich, G, Goldstein, JL, Et, Al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000; 284: 124755.
  • 8
    Bombardier, C, Laine, L, Reicin, A, Et, Al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 9
    Medical Economics, Company. 2000 drug topics red book. Montvale: The Company, 2000.
  • 10
    Maetzel, A, Ferraz, MB, Bombardier, C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998; 41: 1625.
  • 11
    Ehrich, EW, Davies, GM, Watson, DJ, Et, Al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000; 27: 263541.
  • 12
    Anonymous. Vioxx (Rofecoxib) tablets review. Washington: Food and Drug Administration, Center for Drug Evaluation and Research, Division of Anti-Inflammatory, Analgesic, and Opthalmic Drug Products, 1999.
  • 13
    Witter, J. Celebrex capsules (Celecoxib). NDA 20–998/S-009. Washington: Medical Officer Review, Food and Drug Administration, Center for Drug Evaluation and Research, Arthritis Advisory Committee, 2001. p. 1–99.
  • 14
    Langman, M, Jensen, DM, Watson, DJ, Et, Al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929 33.
  • 15
    Anonymous. VIOXX tablets: VIOXX oral suspension (Rofecoxib). VIOXX Gastrointestinal Outcomes Research Study (VIGOR) briefing information. NDA 21–052. Washington: Food Drug Administration, Center for Drug Evaluation Research, Arthritis Advisory Committee, 2001. p. 1–112.
  • 16
    Goldstein, JL, Silverstein, FE, Agrawal, NM, Et, Al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 168190.
    Direct Link:
  • 17
    Anonymous. Celebrex (celecoxib) capsules review: osteoarthritis statistical review. Washington: Food and Drug Administration, Center for Drug Evaluation and Research, Division of Anti-inflammatory, Analgesic, and Opthalmic Drug Products, 1998.
  • 18
    Hernandez-Diaz, S, Rodriguez, LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 20939.
  • 19
    MacDonald, TM, Morant, SV, Robinson, GC, Et, Al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 13337.
  • 20
    Hallas, J, Lauritsen, J, Villadsen, HD, Gram, LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995; 30: 43844.
  • 21
    Lanza, FL, Codispoti, JR, Nelson, EB. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen. Am J Gastroenterol 1998; 93: 10514.
    Direct Link:
  • 22
    Smalley, WE, Ray, WA, Daugherty, JR, Griffin, MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141: 53945.
  • 23
    Andrade, SE, Martinez, C, Walker, AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998; 51: 135765.
  • 24
    Garcia, RLAG, Walker, AM, Gutthann, SP. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992; 3: 33742.
  • 25
    Lanza, LL, Walker, AM, Bortnichak, EA, Dreyer, NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. Arch Intern Med 1995; 155: 13717.
  • 26
    Henry, D, Lim, LL, Garcia Rodriguez, LA, Et, Al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 15636.
  • 27
    Silverstein, FE, Graham, DY, Senior, JR, Et, Al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 28
    Garcia Rodriguez, L, Hernandez-Diaz, S. The relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 5706.
  • 29
    Rahme, E, Pettitt, D, LeLorier, J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum 2002; 46: 304654.
  • 30
    Laporte, JR, Carne, X, Vidal, X, Et, Al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 1991; 337: 859.
  • 31
    Matzke, GR. Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Am J Kidney Dis 1996; 28(Suppl 1): S6370.
  • 32
    Savage, RL, Moller, PW, Ballantyne, CL, Wells, JE. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum 1993; 36: 8490.
  • 33
    Williams, HJ, Ward, JR, Egger, MJ, Et, Al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993; 36: 1196206.
  • 34
    Bradley, JD, Brandt, KD, Katz, BP, Et, Al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 8791.
  • 35
    Geba, GP, Weaver, AL, Polis, AB, Et, Al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee—a randomized trial. JAMA 2001; 287: 6471.
  • 36
    Pincus, T, Koch, GG, Sokka, T, Et, Al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 158798.
  • 37
    Pharmacia, Corporation. US prescribing information for Celebrex [Internet]. Peapack (NJ): The Corporation, 2000 [revised 2000 Apr 24]. Available from: http://www.celebrex.com/u6_important_product_info.asp
  • 38
    Merck & Co. US prescribing information for Vioxx [Internet]. Witehouse Station: The Company, 2000.
  • 39
    Moore, N, Van Ganse, E, JM, LP, Et, Al. The PAIN study: paracetamol, aspirin, and ibuprofen new tolerability study—a large-scale randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest 1999; 18: 8998.
  • 40
    Rahme, E, Joseph, L, Kong, SX, Et, Al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 91724.
  • 41
    Bombardier, C, Laine, L, Reicin, A, Et, Al. Fewer gastrointestinal protective agents, procedures, and hospitalizations with rofecoxib vs. naproxen in the VIGOR (Vioxx Outcomes Research) Study [Abstract]. Arthritis Rheum 2000; 43(Suppl 9): S225.
  • 42
    Choi, HK, Seeger, JD, Kuntz, KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 231627.
  • 43
    Bensen, WG, Fiechtner, JJ, McMillen, JI, Et, Al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clinic Proc 1999; 74: 1095105.
  • 44
    Day, R, Morrison, B, Luza, A, Et, Al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000; 160: 17817.
  • 45
    US Department of Labor Bureau of Labor Statistics. All urban consumer price index for medical care. Washington: Bureau, 2001.
  • 46
    Humber, PJ. Robust estimation of a location parameter. Ann Math Stat 1964; 35: 73101.
  • 47
    Practice Management Information, Corporation. ADP/context medical fees in the United States. Los Angeles: The Corporation, 2000.
  • 48
    Van Hout, BA, Al, MJ, Gordon, GS, Rutten, FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 30919.
  • 49
    Briggs, A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479500.
  • 50
    Stinnett, AA, Paltiel, AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997; 17: 4839.
  • 51
    Holzer, SS, Cuerdon, T. Development of an economic model comparing acetaminophen to NSAIDs in the treatment of mild-to-moderate osteoarthritis. Am J Managcare 1996; II(Suppl S15): 26.
  • 52
    Motheral, BR, Bataoel, JR, Armstrong, EP. A strategy for evaluating the novel COX-2 inhibitors versus NSAIDs for arthritis. Hospital Form 1999; 34: 85563.
  • 53
    Zabinski, RA, Burke, TA, Johnson, J, Et, Al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19(Suppl 1): 4958.
  • 54
    Chancellor, JV, Hunsche, E, De Cruz, E, Sarasin, FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19(Suppl 1): 5975.
  • 55
    Haglund, U, Svarvar, P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(Suppl 2): 516.
  • 56
    Svarvar, P, Aly, A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (Oxford) 2000; 39(Suppl 2): 4350.
  • 57
    Pincus, T, Swearingen, C, Cummins, P, Callahan, LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27: 10207.
  • 58
    Felson, DT. The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments. Arthritis Rheum 2001; 44: 147780.
  • 59
    Langman, M, Kahler, KH, Kong, SX, Et, Al. Drug switching patterns among patients taking non-streroidal anti-inflammatory drugs. a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Safety 2001; 10: 51724.
  • 60
    Walker, AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 1997; 40: 2018.
  • 61
    Ray, WA, Stein, CM, Hall, K, Et, Al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 11823.
  • 62
    Huang, JQ, Sridhar, S, Hunt, RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 1422.
  • 63
    Chan, FKL, To, KF, Wu, JCY, Et, Al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 913.